Last reviewed · How we verify
NCT04888234
Evaluation the Effectiveness of Ru-Yi-Jin-Huang Powder for the Radiation-induced Dermatitis.
Phase 2 trial testing Ru-Yi-Jin-Huang Powder in Radiation Dermatitis in 30 participants. Status unknown.
30 July 2022
Quick facts
| Lead sponsor | Chang Gung Memorial Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 8 May 2021 |
| Primary completion | 30 July 2022 |
| Estimated completion | 30 July 2022 |
Drugs / interventions tested
- Ru-Yi-Jin-Huang Powder
Conditions studied
- Radiation Dermatitis — all drugs for Radiation Dermatitis →
Sponsor
Chang Gung Memorial Hospital
Who can join
Adults 18 to 80, any sex, with Radiation Dermatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Radiation-induced dermatitis is the most common complication of radiotherapy for cancer treatment. However, there is no satisfactory management to deal with the problem. Ru-Yi-Jin-Huang Powder is one of most common topical TCM drug to treat skin diseases but lack of evidence to support efficacy. The aim of this trial is to evaluate the effectiveness of Ru-Yi-Jin-Huang Powder for radiation-induced dermatitis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Ionizing radiation: molecular mechanisms, biological effects, and therapeutic targets.
Wei W, Ren Y, Lan J, Yi J, et al · · 2026 · PMID 41507636 · DOI 10.1186/s43556-025-00358-4
Verify or expand the search:
- PubMed search for NCT04888234
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Radiation Dermatitis
Currently open trials in the same condition.
- NCT07086638 — ROS-Scavenging Nanozyme Combined With Thermotherapy Alleviate Radiation Dermatitis in Patients With Head and Neck Cancer · NA · recruiting
- NCT07081074 — ROS-scavenging Amino Acid-derived Lipids for the Prevention and Treatment of Radiation Dermatitis in Patients With Head · NA · recruiting
- NCT07064577 — Novel ROS-scavenging Nanoenzymes for the Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer · NA · recruiting
- NCT06915857 — Topical Betamethasone Versus Moisturizer in Preventing Radiation Dermatitis in Large-Breasted Patients Treated in the Pr · Phase 3 · recruiting
- NCT06729814 — Prospective Assessment of Acute Skin Toxicities in Breast Cancer Patients Undergoing Retreatment with 40 Gy in 15 Fracti · recruiting
Other Chang Gung Memorial Hospital trials
Trials by the same sponsor.
- NCT07419789 — Precision Care for Older Persons · NA · not yet recruiting
- NCT07248345 — Virtual Reality Intervention for Family Caregivers of Persons Living With Dementia · NA · not yet recruiting
- NCT07036978 — Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer · not yet recruiting
- NCT07489833 — Metabolomic Pathways and Traditional Chinese Medicine Body Constitution in Cancer-related Fatigue · not yet recruiting
- NCT07496528 — The ACURE Trial: Acupuncture for Colorectal Recovery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04888234 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chang Gung Memorial Hospital
- Last refreshed: 17 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04888234.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing